FMF-04-159-2
CAS No.
FMF-04-159-2 ( —— )
Catalog No. M16940 CAS No.
FMF-04-159-2 is a potent, selective, covalent CDK14 inhibitor (IC50=86 nM) with pan-TAIRE family specificity (CDKs 14-18).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
100MG | Get Quote | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameFMF-04-159-2
-
NoteResearch use only, not for human use.
-
Brief DescriptionFMF-04-159-2 is a potent, selective, covalent CDK14 inhibitor (IC50=86 nM) with pan-TAIRE family specificity (CDKs 14-18).
-
DescriptionFMF-04-159-2 is a potent, selective, covalent CDK14 inhibitor (IC50=86 nM) with pan-TAIRE family specificity (CDKs 14-18); potently inhibited the TAIRE kinases CDK14, CDK16, CDK17, and CDK18; CDK14 was potently engaged by FMF-04-159-2 (IC50=39.6 nM), and this engagement was sustained after a 2-h, compound washout (IC50=56.3 nM), indicates irreversible binding; FMF-04-159-2 is a valuable tool for study of CDK14 kinase function.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number--
-
Formula Weight683.00
-
Molecular FormulaC28H30Cl3N7O5S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name(E)-N-(1-((3-(4-(dimethylamino)but-2-enamido)phenyl)sulfonyl)piperidin-4-yl)-4-(2,4,6-trichlorobenzamido)-1H-pyrazole-3-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ferguson FM, et al. Cell Chem Biol. 2019 Mar 11. pii: S2451-9456(19)30070-4.
molnova catalog
related products
-
PNU-112455A
PNU-112455A is an ATP-competitive CDK2/5 inhibitor with Ki of 2 uM and 2 uM for cdk2·GST-cyclin E and cdk5·GST-p25 respectively.
-
BAY-1251152
(±)-BAY-1251152 is a racemic mixture of BAY-1251152. BAY-1251152 is highly selective inhibitor of PTEF/CDK9.
-
TAK-931
TAK-931 (Simurosertib) is a potent, selective, ATP competitive and orally bioavailable inhibitor of Cdc7 with IC50 of <0.3 nM.